Daniel S. Chen

Oncology · Nature · 2013–2020

A researcher in the Science corpus: 10 papers; trusts 10 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 223 citations into it; #637 of 1,698 by trust here, #58 by citations
• Immunology — 156 citations into it; #883 of 2,160 by trust here, #136 by citations

Whom Daniel S. Chen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. T. Gajewski
2. S. Topalian
3. I. Mellman
4. Greg T. Motz
5. George Coukos
6. B. Lippitz
7. Daniel S. Chen
8. D. Pardoll
9. Jérôme Galon
10. Matthew Vanneman

Who trusts Daniel S. Chen overall

1. T. Hirano
2. S. Farkona
3. V. Gopalakrishnan
4. Yuan-Tong Liu
5. Ugur Sahin
6. Ton N. Schumacher
7. B. Ruffell
8. D. Thommen
9. Alycia Gardner
10. C. Yun

Papers from Daniel S. Chen's perspective

Ordered by how strongly the researchers Daniel S. Chen trusts endorse each paper. Same corpus, a different order for every researcher.

1. Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
2. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (New England Journal of Medicine)
3. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (Molecular and Cellular Biology)
4. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
5. Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients (New England Journal of Medicine)
6. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
7. Cancer immunotherapy comes of age (Nature)
8. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
9. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (Immunity)
10. Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors (Nature Medicine)

Their papers

• Top 10 Challenges in Cancer Immunotherapy. (2020) — 1,779 citations
• Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) — 1,089 citations
• TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells (2018) — 4,528 citations
• Elements of cancer immunity and the cancer–immune set point (2017) — 4,557 citations
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. (2016) — 2,545 citations
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2016) — 4,239 citations
• Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma (2016) — 648 citations
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014) — 2,264 citations
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (2014) — 4,940 citations
• Oncology meets immunology: the cancer-immunity cycle. (2013) — 6,077 citations